Immunotherapy in Renal Cell Carcinoma: The Future Is Now

被引：181

作者：

Deleuze, Antoine ^{[1
,2
]}

Saout, Judikael ^{[1
]}

Dugay, Frederic ^{[1
,3
]}

Peyronnet, Benoit ^{[4
]}

Mathieu, Romain ^{[1
,4
]}

Verhoest, Gregory ^{[4
]}

Bensalah, Karim ^{[4
]}

Crouzet, Laurence ^{[2
]}

Laguerre, Brigitte ^{[2
]}

Belaud-Rotureau, Marc-Antoine ^{[1
,3
]}

Rioux-Leclercq, Nathalie ^{[1
,5
]}

Kammerer-Jacquet, Solene-Florence ^{[1
,5
]}

机构：

[1] Univ Rennes, EHESP Ecole Hautes Etud Sante Publ, IRSET Inst Rech Sante Environm & Travail, Inserm,UMR 1085, F-35000 Rennes, France

[2] Ctr Eugene Marquis, Dept Med Oncol, F-35000 Rennes, France

[3] Univ Hosp, Dept Cytogenet, F-35000 Rennes, France

[4] Univ Hosp, Dept Urol, F-35000 Rennes, France

[5] Univ Hosp, Dept Pathol, F-35000 Rennes, France

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 07期

关键词：

immunotherapy; immune checkpoint inhibitors; renal cell carcinoma; PD-1; PD-L1; ongoing trials; biomarkers; emerging drugs; TUMOR-CELLS; PD-L1; EXPRESSION; INTERFERON-ALPHA; SUNITINIB; NIVOLUMAB; EVEROLIMUS; RESISTANCE; INHIBITION; RECEPTORS; THERAPIES;

D O I：

10.3390/ijms21072532

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare with a high rate of resistance. New strategies are emerging to improve the efficacy and the emerging drugs are under evaluation in ongoing trials. With the different treatment options, there is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients. Owing to the limitations of programmed death-ligand 1 (PD-L1), the most studied immunohistochemistry biomarkers, and of the tumor mutational burden, the identification of more reliable markers is an unmet need. New technologies could help in this purpose.

引用

页数：22

共 97 条

[61] Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations [J].

Malouf, Gabriel G. ;

Ali, Siraj M. ;

Wang, Kai ;

Balasubramanian, Sohail ;

Ross, Jeffrey S. ;

Miller, Vincent A. ;

Stephens, Philip J. ;

Khayat, David ;

Pal, Sumanta K. ;

Su, Xiaoping ;

Sircar, Kanishka ;

Tamboli, Pheroze ;

Jonasch, Eric ;

Tannir, Nizar M. ;

Wood, Christopher G. ;

Karam, Jose A. .

EUROPEAN UROLOGY, 2016, 70 (02) :348-357

[62] Genomic Heterogeneity of Translocation Renal Cell Carcinoma [J].

Malouf, Gabriel G. ;

Monzon, Federico A. ;

Couturier, Jerome ;

Molinie, Vincent ;

Escudier, Bernard ;

Camparo, Philippe ;

Su, Xiaoping ;

Yao, Hui ;

Tamboli, Pheroze ;

Lopez-Terrada, Dolores ;

Picken, Maria ;

Garcia, Marileila ;

Multani, Asha S. ;

Pathak, Sen ;

Wood, Christopher G. ;

Tannir, Nizar M. .

CLINICAL CANCER RESEARCH, 2013, 19 (17) :4673-4684

[63] Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma [J].

McDermott, David F. ;

Huseni, Mahrukh A. ;

Atkins, Michael B. ;

Motzer, Robert J. ;

Rini, Brian I. ;

Escudier, Bernard ;

Fong, Lawrence ;

Joseph, Richard W. ;

Pal, Sumanta K. ;

Reeves, James A. ;

Sznol, Mario ;

Hainsworth, John ;

Rathmell, W. Kimryn ;

Stadler, Walter M. ;

Hutson, Thomas ;

Gore, Martin E. ;

Ravaud, Alain ;

Bracarda, Sergio ;

Suarez, Cristina ;

Danielli, Riccardo ;

Gruenwald, Viktor ;

Choueiri, Toni K. ;

Nickles, Dorothee ;

Jhunjhunwala, Suchit ;

Piault-Louis, Elisabeth ;

Thobhani, Alpa ;

Qiu, Jiaheng ;

Chen, Daniel S. ;

Hegde, Priti S. ;

Schiff, Christina ;

Fine, Gregg D. ;

Powles, Thomas .

NATURE MEDICINE, 2018, 24 (06) :749-+

[64]

Meijer TG, 2017, FUTUR SCI OA, V3, DOI 10.4155/fsoa-2017-0003

[65] Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma [J].

Miao, Diana ;

Margolis, Claire A. ;

Gao, Wenhua ;

Voss, Martin H. ;

Li, Wei ;

Martini, Dylan J. ;

Norton, Craig ;

Bosse, Dominick ;

Wankowicz, Stephanie M. ;

Cullen, Dana ;

Horak, Christine ;

Wind-Rotolo, Megan ;

Tracy, Adam ;

Giannakis, Marios ;

Hodi, Frank Stephen ;

Drake, Charles G. ;

Ball, Mark W. ;

Allaf, Mohamad E. ;

Snyder, Alexandra ;

Hellmann, Matthew D. ;

Ho, Thai ;

Motzer, Robert J. ;

Signoretti, Sabina ;

Kaelin, William G., Jr. ;

Choueiri, Toni K. ;

Van Allen, Eliezer M. .

SCIENCE, 2018, 359 (6377) :801-805

[66] The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours [J].

Moch, Holger ;

Cubilla, Antonio L. ;

Humphrey, Peter A. ;

Reuter, Victor E. ;

Ulbright, Thomas M. .

EUROPEAN UROLOGY, 2016, 70 (01) :93-105

[67] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Tannir, N. M. ;

McDermott, D. F. ;

Frontera, O. Aren ;

Melichar, B. ;

Choueiri, T. K. ;

Plimack, Elizabeth R. ;

Barthelemy, P. ;

Porta, C. ;

George, S. ;

Powles, T. ;

Donskov, F. ;

Neiman, V. ;

Kollmannsberger, C. K. ;

Salman, P. ;

Gurney, H. ;

Hawkins, R. ;

Ravaud, A. ;

Grimm, M. -O. ;

Bracarda, S. ;

Barrios, C. H. ;

Tomita, Y. ;

Castellano, D. ;

Rini, B. I. ;

Chen, A. C. ;

Mekan, S. ;

McHenry, M. B. ;

Wind-Rotolo, M. ;

Doan, J. ;

Sharma, P. ;

Hammers, H. J. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) :1277-1290

[68] Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Escudier, B. ;

McDermott, D. F. ;

George, S. ;

Hammers, H. J. ;

Srinivas, S. ;

Tykodi, S. S. ;

Sosman, J. A. ;

Procopio, G. ;

Plimack, E. R. ;

Castellano, D. ;

Choueiri, T. K. ;

Gurney, H. ;

Donskov, F. ;

Bono, P. ;

Wagstaff, J. ;

Gauler, T. C. ;

Ueda, T. ;

Tomita, Y. ;

Schutz, F. A. ;

Kollmannsberger, C. ;

Larkin, J. ;

Ravaud, A. ;

Simon, J. S. ;

Xu, L-A ;

Waxman, I. M. ;

Sharma, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1803-1813

[69]

Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289

[70] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial [J].

Motzer, Robert ;

Rini, Brian, I ;

McDermott, David F. ;

Frontera, Osvaldo Aren ;

Hammers, Hans J. ;

Carducci, Michael A. ;

Salman, Pamela ;

Escudier, Bernard ;

Beuselinck, Benoit ;

Amin, Asim ;

Porta, Camillo ;

George, Saby ;

Neiman, Victoria ;

Bracarda, Sergio ;

Tykodi, Scott S. ;

Barthelemy, Philippe ;

Leibowitz-Amit, Raya ;

Plimack, Elizabeth R. ;

Oosting, Sjoukje F. ;

Redman, Bruce ;

Melichar, Bohusiav ;

Powles, Thomas ;

Nathan, Paul ;

Oudard, Stephan ;

Pook, David ;

Choueiri, Toni K. ;

Donskov, Frede ;

Grimm, Marc-Oliver ;

Gurney, Howard ;

Heng, Daniel Y. C. ;

Kollmannsberger, Christian K. ;

Harrison, Michael R. ;

Tamita, Yoshihiko ;

Duran, Ignacio ;

Gruenwold, Viktor ;

McHenry, M. Brent ;

Mekan, Sabeen ;

Tannir, Nizar M. .

LANCET ONCOLOGY, 2019, 20 (10) :1370-1385

← 1 2 3 4 5 6 7 8 9 10 →